세계의 담도암 치료 시장 2019-2023

■ 영문 제목 : Global Cholangiocarcinoma Therapeutics Market 2019-2023

Technavio가 발행한 조사보고서이며, 코드는 IRTNTR30865 입니다.■ 상품코드 : IRTNTR30865
■ 조사/발행회사 : Technavio
■ 발행일 : 2019년 2월 14일
■ 페이지수 : 117
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 글로벌, 미주, 유럽, 아시아
■ 산업 분야 : 의료
■ 판매가격 / 옵션 (부가세별도)
Single User (1명 열람용)USD2,500 ⇒환산₩3,000,000견적의뢰/주문/질문
Five User (5명 열람용)USD3,000 ⇒환산₩3,600,000견적의뢰/주문/질문
Enterprise License (전사내 공유가능)USD4,000 ⇒환산₩4,800,000견적의뢰/구입/질문
가격옵션 설명
- 지불하실 금액은 상기 원화금액에 부가세(10%)를 더한 금액입니다.
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제이며, 납품후 5일이내에 청구서를 발행/송부합니다.
본 조사보고서는 담도암 치료의 세계시장에 대해서 조사분석한 자료로서, 담도암 치료의 세계시장규모, 시장동향, 시장환경 분석, 세그멘트별 분석, 지역별 분석 (미주, 유럽, 아시아), 관련기업 정보등이 포함되어 있습니다.
■ 보고서 개요

About this marketCholangiocarcinoma is one of the rare types of cancers globally, as a result, the market does not have approved therapies in abundance. The dominance of these drugs is affecting the interest of new vendors to conduct research on developing novel therapies. To overcome this challenge, several research institutes are coming up with various programs to treat patients with intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma. The support from the institute is also coming in the form of new chemotherapy combinations for treating both types of cholangiocarcinoma. Similarly, various other research institutions are also working on providing treatment to the patients, and the increasing support from these institutes is expected to contribute significantly to the growth of the global cholangiocarcinoma therapeutics market during the forecast period. Technavio’s analysts have predicted that the cholangiocarcinoma therapeutics market will register a CAGR of almost 6% by 2023.
Market Overview
Growing usage of combination there
The global cholangiocarcinoma therapeutics market has a limited number of treatment options, among which the most preferred treatment option is surgeries due to the lack of efficacy of therapeutics in the late stages of the disease. To overcome this, the market is witnessing an increase in the use of combination of chemotherapies to treat the disease.
Dominance of surgery
The global cholangiocarcinoma therapeutics market faces a heavy threat from surgeries, as they are currently the most preferred treatment option available to the patients. As a result, surgeries are gaining popularity for the treatment of both intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma, which is expected to have a negative impact on the growth of the global cholangiocarcinoma therapeutics market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the cholangiocarcinoma therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fairly concentrated and with the presence of few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

■ 보고서 목차

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Intrahepatic cholangiocarcinoma – Market size and forecast 2018-2023
• Extrahepatic cholangiocarcinoma – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market
Exhibit 08: Global market
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 18: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Intrahepatic cholangiocarcinoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Intrahepatic cholangiocarcinoma – Year-over-year growth 2019-2023 (%)
Exhibit 23: Extrahepatic cholangiocarcinoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Extrahepatic cholangiocarcinoma – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bristol-Myers Squibb Company – Vendor overview
Exhibit 46: Bristol-Myers Squibb Company – Business segments
Exhibit 47: Bristol-Myers Squibb Company – Organizational developments
Exhibit 48: Bristol-Myers Squibb Company – Geographic focus
Exhibit 49: Bristol-Myers Squibb Company – Key offerings
Exhibit 50: Bristol-Myers Squibb Company – Key customers
Exhibit 51: Eli Lilly and Company – Vendor overview
Exhibit 52: Eli Lilly and Company – Business segments
Exhibit 53: Eli Lilly and Company – Organizational developments
Exhibit 54: Eli Lilly and Company – Geographic focus
Exhibit 55: Eli Lilly and Company – Segment focus
Exhibit 56: Eli Lilly and Company – Key offerings
Exhibit 57: Eli Lilly and Company – Key customers
Exhibit 58: F. Hoffmann-La Roche Ltd – Vendor overview
Exhibit 59: F. Hoffmann-La Roche Ltd – Business segments
Exhibit 60: F. Hoffmann-La Roche Ltd – Organizational developments
Exhibit 61: F. Hoffmann-La Roche Ltd – Geographic focus
Exhibit 62: F. Hoffmann-La Roche Ltd – Segment focus
Exhibit 63: F. Hoffmann-La Roche Ltd – Key offerings
Exhibit 64: F. Hoffmann-La Roche Ltd – Key customers
Exhibit 65: Pfizer Inc. – Vendor overview
Exhibit 66: Pfizer Inc. – Business segments
Exhibit 67: Pfizer Inc. – Organizational developments
Exhibit 68: Pfizer Inc. – Geographic focus
Exhibit 69: Pfizer Inc. – Segment focus
Exhibit 70: Pfizer Inc. – Key offerings
Exhibit 71: Pfizer Inc. – Key customers
Exhibit 72: Sanofi – Vendor overview
Exhibit 73: Sanofi – Business segments
Exhibit 74: Sanofi – Organizational developments
Exhibit 75: Sanofi – Geographic focus
Exhibit 76: Sanofi – Segment focus
Exhibit 77: Sanofi – Key offerings
Exhibit 78: Sanofi – Key customers
Exhibit 79: Validation techniques employed for market sizing



■ 기재된 기업 리스트

Bristol-Myers Squibb Company, Eli Lilly Company, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi


■ 보고서의 키워드

담도암 치료


■ 조사 방법

Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.

※본 조사보고서 [세계의 담도암 치료 시장 2019-2023] (코드 : IRTNTR30865) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 담도암 치료 시장 2019-2023] 에 대해서 E메일 문의는 여기를 클릭하세요.